bioRxiv Science⌕ Search

Biology subjects

Fais, F.

Publications and source records attributed to Fais, F..

2 recordsLinked to original sources

Asymmetric induction of IL-23R by CpG and IL-15 in proliferative CLL fractions highlights intraclonal heterogeneity in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is sustained by complex interactions with the microenvironment, which provides signals for leukemic cell survival and proliferation. Among these, cytokines of the IL-12 family have emerged as relevant regulators of immune responses and tumor biology, yet their contribution to CLL remains incompletely defined. Previous studies showed that CLL cells can acquire responsiveness to IL-23 after T cell-dependent stimulation with CD40L, raising the question of whether T cell-independent signals can similarly induce functional receptor expression. Here we investigated the effect of CpG oligodeoxynucleotides, alone or in combination with interleukin-15 (IL-15), on IL-12 family receptor expression in CLL cells. We found that CpG + IL-15 stimulation significantly increased IL-23R and IL-12R{beta}1 expression, while IL-12R{beta}2 remained largely unresponsive. As a consequence, the complete IL-23 receptor complex was robustly induced, whereas IL-12 receptor assembly was only marginally enhanced. This skewing toward IL-23 rather than IL-12 signaling suggests that innate immune stimuli preferentially promote pathways supporting inflammation and survival, while limiting tumor-suppressive IL-12 responsiveness. Analysis of intraclonal heterogeneity revealed an asymmetric distribution of IL-23R among CXCR4/CD5-defined subfractions: the proliferative fraction, representing recently divided cells, expressed higher levels of IL-23R compared to the resting fraction. These findings suggest that IL-23 responsiveness is particularly enriched in the proliferating compartment of the leukemic clone. Overall, our results indicate that CpG and IL-15 stimulation drive a selective expansion of IL-23 signaling capacity in CLL, with preferential engagement of proliferative subfractions. This imbalance between IL-23 activation and insufficient IL-12R{beta}2 induction may represent a critical pathogenic mechanism and a potential therapeutic target.

cancer biology↗

Drug-free nasal spray as a barrier against SARS-CoV-2 infection: safety and efficacy in human nasal airway epithelia

BackgroundFor SARS-CoV-2 and other respiratory viruses, the nasal epithelium is a key portal for infection. Therefore, the nose is an important target of prophylactic and therapeutic interventions against these viruses. We developed a nasal spray (AM-301, a medical device marketed as Bentrio) to protect against infection by SARS-CoV-2 and potentially other viruses. Aims of the studyTo test the safety and efficacy of AM-301 against SARS-CoV-2 infection. MethodsAM-301 was tested on an in vitro 3D model of primary human nasal airway epithelium. Safety was assessed in assays for tight junction integrity, cytotoxicity and cilia beating frequency. Efficacy against SARS-CoV-2 infection was evaluated in prophylaxis and infection mitigation assays. ResultsAM-301 did not have any detrimental effect on the nasal epithelium. Prophylactic treatment with AM-301 reduced viral titer significantly vs. controls over 4 days, reaching a maximum reduction of 99%. When treatment with AM-301 was started 24 or 30 h after infection, epithelia that received the formulation had a 12- or 14-fold lower titer than controls. ConclusionAM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. Its physical (non-pharmaceutical) mechanism of action, safety and efficacy pave the way for further investigation of its possible use against a broad spectrum of viruses, allergens and pollutants.

pharmacology and toxicology↗